NewAmsterdam Pharma (NASDAQ:NAMS) Announces Quarterly Earnings Results, Beats Estimates By $0.35 EPS

NewAmsterdam Pharma (NASDAQ:NAMS) posted its quarterly earnings results on Wednesday. The company reported ($0.14) earnings per share for the quarter, beating the consensus estimate of ($0.49) by $0.35, FiscalAI reports. NewAmsterdam Pharma had a negative return on equity of 34.81% and a negative net margin of 3,644.21%. The firm had revenue of $19.16 million for the quarter, compared to analyst estimates of $7.54 million.

NewAmsterdam Pharma Price Performance

NASDAQ:NAMS traded up $0.81 during mid-day trading on Wednesday, reaching $20.71. The stock had a trading volume of 1,473,854 shares, compared to its average volume of 1,171,273. The business’s 50 day moving average is $22.56 and its 200 day moving average is $29.71. NewAmsterdam Pharma has a fifty-two week low of $19.13 and a fifty-two week high of $42.21. The stock has a market cap of $2.48 billion, a P/E ratio of -9.59 and a beta of 0.15.

Analysts Set New Price Targets

A number of research firms have recently issued reports on NAMS. HC Wainwright reissued a “buy” rating and issued a $52.00 price target on shares of NewAmsterdam Pharma in a research report on Tuesday, September 8th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of NewAmsterdam Pharma in a research report on Thursday, October 15th. BMO Capital Markets began coverage on shares of NewAmsterdam Pharma in a research note on Monday, July 20th. They issued an “outperform” rating and a $58.00 price objective on the stock. Jefferies Financial Group reiterated a “buy” rating and issued a $45.00 target price on shares of NewAmsterdam Pharma in a research report on Monday, July 20th. Finally, Royal Bank Of Canada decreased their target price on shares of NewAmsterdam Pharma from $50.00 to $42.00 and set an “outperform” rating for the company in a research note on Monday, October 5th. One research analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $48.90.

Insider Activity at NewAmsterdam Pharma

In other NewAmsterdam Pharma news, CEO Michael H. Davidson purchased 10,000 shares of the company’s stock in a transaction dated Monday, September 14th. The shares were bought at an average price of $22.65 per share, for a total transaction of $226,500.00. Following the purchase, the chief executive officer directly owned 792,923 shares in the company, valued at $17,959,705.95. This trade represents a 1.28% increase in their position. The purchase was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, Director John W. Smither sold 1,600 shares of the firm’s stock in a transaction on Friday, September 4th. The shares were sold at an average price of $25.32, for a total transaction of $40,512.00. Following the transaction, the director owned 8,760 shares in the company, valued at $221,803.20. This represents a 15.44% decrease in their position. The SEC filing for this sale provides additional information. Over the last quarter, insiders have sold 176,846 shares of company stock valued at $4,661,919. 12.74% of the stock is currently owned by corporate insiders.

NewAmsterdam Pharma Company Profile

NewAmsterdam Pharma (NASDAQ: NAMS) is a clinical-stage biopharmaceutical company focused on developing therapies for cardiometabolic diseases. The company’s primary investigational product is obicetrapib, an oral, low-dose cholesteryl ester transfer protein (CETP) inhibitor designed to reduce low-density lipoprotein cholesterol and potentially address residual cardiovascular risk in patients who remain inadequately controlled on existing treatments.

NewAmsterdam is evaluating obicetrapib in late-stage clinical studies involving patients with dyslipidemia, including individuals with heterozygous familial hypercholesterolemia and patients who are unable to reach cholesterol goals with currently available therapies.